186 related articles for article (PubMed ID: 26988235)
1. [High levels of atrial natriuretic peptide and copeptin and mortality risk].
Rey C; García-Cendón C; Martínez-Camblor P; López-Herce J; Concha-Torre A; Medina A; Vivanco-Allende A; Mayordomo-Colunga J
An Pediatr (Barc); 2016 Dec; 85(6):284-290. PubMed ID: 26988235
[TBL] [Abstract][Full Text] [Related]
2. Maternal serum copeptin, MR-proANP and procalcitonin levels at 11-13 weeks gestation in the prediction of preeclampsia.
Birdir C; Janssen K; Stanescu AD; Enekwe A; Kasimir-Bauer S; Gellhaus A; Kimmig R; Köninger A
Arch Gynecol Obstet; 2015 Nov; 292(5):1033-42. PubMed ID: 25975456
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
[TBL] [Abstract][Full Text] [Related]
4. Comparing the accuracy of predictors of mortality in ventilator-associated pneumonia.
Seligman R; Seligman BG; Teixeira PJ
J Bras Pneumol; 2011; 37(4):495-503. PubMed ID: 21881740
[TBL] [Abstract][Full Text] [Related]
5. Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ.
Krüger S; Papassotiriou J; Marre R; Richter K; Schumann C; von Baum H; Morgenthaler NG; Suttorp N; Welte T;
Intensive Care Med; 2007 Dec; 33(12):2069-78. PubMed ID: 17938883
[TBL] [Abstract][Full Text] [Related]
6. Outcome prediction and temperature dependency of MR-proANP and Copeptin in comatose resuscitated patients.
Broessner G; Hasslacher J; Beer R; Lackner P; Lehner GF; Harler U; Schiefecker A; Helbok R; Pfausler B; Hammerer-Lercher A; Joannidis M
Resuscitation; 2015 Apr; 89():75-80. PubMed ID: 25619444
[TBL] [Abstract][Full Text] [Related]
7. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia.
Masiá M; Papassotiriou J; Morgenthaler NG; Hernández I; Shum C; Gutiérrez F
Clin Chem; 2007 Dec; 53(12):2193-201. PubMed ID: 17951293
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of MR-proANP and copeptin for sepsis diagnosis after burn injury.
Gille J; Schmidt J; Kremer T; Sablotzki A
J Crit Care; 2019 Aug; 52():149-155. PubMed ID: 31075618
[TBL] [Abstract][Full Text] [Related]
9. Circulating levels of pro-atrial natriuretic peptide in lower respiratory tract infections.
Müller B; Süess E; Schuetz P; Müller C; Bingisser R; Bergmann A; Stolz D; Tamm M; Morgenthaler NG; Christ-Crain M
J Intern Med; 2006 Dec; 260(6):568-76. PubMed ID: 17116008
[TBL] [Abstract][Full Text] [Related]
10. MR-proANP, MR-proADM, and PCT in Patients Presenting with Acute Dyspnea in a Medical Emergency Unit.
Heining L; Giesa C; Ewig S
Lung; 2016 Apr; 194(2):185-91. PubMed ID: 26748496
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients.
Cinar O; Cevik E; Acar A; Kaya C; Ardic S; Comert B; Yokusoglu M; Bilgi C; Meisner M; Madsen T
Am J Emerg Med; 2012 Nov; 30(9):1915-20. PubMed ID: 22742951
[TBL] [Abstract][Full Text] [Related]
12. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure.
Miller WL; Hartman KA; Grill DE; Struck J; Bergmann A; Jaffe AS
Heart; 2012 Mar; 98(5):389-94. PubMed ID: 22194151
[TBL] [Abstract][Full Text] [Related]
13. Atrial natriuretic peptide, copeptin and adrenomedullin levels in polycystic ovary syndrome: a case-control study.
Frøssing S; Nylander M; Aziz M; Skouby SO; Kistorp C; Faber J
Gynecol Endocrinol; 2017 Jan; 33(1):30-33. PubMed ID: 27424881
[TBL] [Abstract][Full Text] [Related]
14. Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study.
Sujana C; Seissler J; Jordan J; Rathmann W; Koenig W; Roden M; Mansmann U; Herder C; Peters A; Thorand B; Then C
Cardiovasc Diabetol; 2020 Oct; 19(1):178. PubMed ID: 33066780
[TBL] [Abstract][Full Text] [Related]
15. Midregional pro-atrial natriuretic peptide and procalcitonin improve survival prediction in VAP.
Boeck L; Eggimann P; Smyrnios N; Pargger H; Thakkar N; Siegemund M; Marsch S; Rakic J; Tamm M; Stolz D
Eur Respir J; 2011 Mar; 37(3):595-603. PubMed ID: 20530040
[TBL] [Abstract][Full Text] [Related]
16. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).
O'Malley RG; Bonaca MP; Scirica BM; Murphy SA; Jarolim P; Sabatine MS; Braunwald E; Morrow DA
J Am Coll Cardiol; 2014 Apr; 63(16):1644-53. PubMed ID: 24530676
[TBL] [Abstract][Full Text] [Related]
17. Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study.
Düngen HD; Tscholl V; Obradovic D; Radenovic S; Matic D; Musial Bright L; Tahirovic E; Marx A; Inkrot S; Hashemi D; Veskovic J; Apostolovic S; von Haehling S; Doehner W; Cvetinovic N; Lainscak M; Pieske B; Edelmann F; Trippel T; Loncar G
ESC Heart Fail; 2018 Apr; 5(2):288-296. PubMed ID: 29476612
[TBL] [Abstract][Full Text] [Related]
18. Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD.
Fatemi S; Acosta S; Gottsäter A; Melander O; Engström G; Dakhel A; Zarrouk M
Biomarkers; 2019 Sep; 24(6):615-621. PubMed ID: 31215249
[No Abstract] [Full Text] [Related]
19. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.
Pavo N; Raderer M; Hülsmann M; Neuhold S; Adlbrecht C; Strunk G; Goliasch G; Gisslinger H; Steger GG; Hejna M; Köstler W; Zöchbauer-Müller S; Marosi C; Kornek G; Auerbach L; Schneider S; Parschalk B; Scheithauer W; Pirker R; Drach J; Zielinski C; Pacher R
Heart; 2015 Dec; 101(23):1874-80. PubMed ID: 26416836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
